Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.